经皮支气管动脉灌注化疗联合免疫治疗晚期肺癌的回顾性临床观察
Journal: Basic Medical Theory Research DOI: 10.32629/bmtr.v8i1.18600
Abstract
目的：经皮支气管动脉灌注化疗联合免疫检查点抑制剂治疗肺癌的临床疗效和安全性。方法：回顾性分析2023年10月至2025年7月黄河三门峡医院收治的晚期肺癌患者共9例,所有患者入院后病理证实为肺癌。根据治疗方法将所有组进行分析观察。结果：经皮支气管动脉灌注化疗(BAI)(白蛋白结合型紫杉醇+卡铂)联合免疫检查点抑制剂治疗晚期肺癌患者,显示出一定的抗肿瘤活性(ORR66.6%,DCR90%)和可接受的安全性(以1-2级不良反应为主)。结论：经皮支气管动脉灌注化疗(BAI)联合免疫检查点抑制剂治疗能有效地控制中晚期肺鳞癌,近期疗效明确,抑制肿瘤生长,延长患者的无疾病进展生存期,有延长总生存期的趋势,安全性好。
Keywords
支气管动脉；灌注化疗；肺癌；免疫检查点抑制剂
Full Text
PDF - Viewed/Downloaded: 2 TimesReferences
[1] 李靖康,徐爱晖.17例肺癌患者临床特征分析[J].临床肺科杂志,2018,23(5):905-908.
[2] Tsironis G,Ziogas DC,Kyriazoglou A,et al. Breakthroughs in the treatment of advanced squamous cell NSCLC: not the neglected sibling anymore?[J].Ann Transl Med,2018,6(3):43.
[3] Nakanishi M, Umeda Y, Demura Y, et al.Effective use of bronchial artery infusion and arterial embolization for loca lly advanced lung cancer[J].Jpn J Clin Oncol. 2000;30(9):377-381.
[4] Zhou B,Wang J,Yan Z,et al.Bronchial artery infusion che motherapy for advanced non-small cell lung cancer: a systema tic review and meta-analysis[J].J Thorac Dis. 2019;11(3):1031 -1041.
[5] National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer[J].Version [Latest Version Number, e.g.,3.2024].[Accessed Date].
[6] 方文峰,张力.2023年度非小细胞肺癌免疫治疗研究进展
[7] [J].肿瘤综合治疗电子杂志,2024,(10):25-32.
[8] GalluzziL,Buqué A,Kepp O,Zitvogel L,Kroemer G.Immunog enic cell death in cancer and infectious disease[J].Nat Rev Immunol.2017;17(2):97-111.
[9] Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M,Formenti SC.Radiation fosters dose-depende nt and chemotherapy-induced immunogenic cell death[J].Onco immunology.2014;3:e28518.
[10] Vincent J,Mignot G,Chalmin F,et al.5-Fluorouracil sele ctively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immu nity[J].Cancer Res.2010;70(8):3052-3061.
[11] Zhou J,Sun H,Wang Z,et al.Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J].Liver Cancer.2023;12(1):18-39.
[2] Tsironis G,Ziogas DC,Kyriazoglou A,et al. Breakthroughs in the treatment of advanced squamous cell NSCLC: not the neglected sibling anymore?[J].Ann Transl Med,2018,6(3):43.
[3] Nakanishi M, Umeda Y, Demura Y, et al.Effective use of bronchial artery infusion and arterial embolization for loca lly advanced lung cancer[J].Jpn J Clin Oncol. 2000;30(9):377-381.
[4] Zhou B,Wang J,Yan Z,et al.Bronchial artery infusion che motherapy for advanced non-small cell lung cancer: a systema tic review and meta-analysis[J].J Thorac Dis. 2019;11(3):1031 -1041.
[5] National Comprehensive Cancer Network (NCCN).NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Non-Small Cell Lung Cancer[J].Version [Latest Version Number, e.g.,3.2024].[Accessed Date].
[6] 方文峰,张力.2023年度非小细胞肺癌免疫治疗研究进展
[7] [J].肿瘤综合治疗电子杂志,2024,(10):25-32.
[8] GalluzziL,Buqué A,Kepp O,Zitvogel L,Kroemer G.Immunog enic cell death in cancer and infectious disease[J].Nat Rev Immunol.2017;17(2):97-111.
[9] Golden EB, Frances D, Pellicciotta I, Demaria S, Helen Barcellos-Hoff M,Formenti SC.Radiation fosters dose-depende nt and chemotherapy-induced immunogenic cell death[J].Onco immunology.2014;3:e28518.
[10] Vincent J,Mignot G,Chalmin F,et al.5-Fluorouracil sele ctively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immu nity[J].Cancer Res.2010;70(8):3052-3061.
[11] Zhou J,Sun H,Wang Z,et al.Guidelines for the Diagnosis and Treatment of Primary Liver Cancer (2022 Edition)[J].Liver Cancer.2023;12(1):18-39.
Copyright © 2026 李小龙
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License